PER 1.23% 8.0¢ percheron therapeutics limited

UPDATE ON PFIZER’S PHASE 1B OPEN-LABEL MINI-DYSTROPHIN GENE THERAPY TRIAL FOR DUCHENNE, page-3

  1. 3,549 Posts.
    lightbulb Created with Sketch. 771
    Very sad and unfortunate...but Pfizer's loss is ANP s gain...

    It's just amazing if we look at the events and a repeat..CR last year around OCT .same as this year..

    Sarepta and someone else's trials failed and same happened again..

    Brokers reports were out as soon as Sarepta failed and out SP had a run FROM 9.4 to 27c...can we repeat this again??

    Why not ...already oversold and highly undervalued with the progress...

    Let's go ANP..
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
-0.001(1.23%)
Mkt cap ! $72.12M
Open High Low Value Volume
8.2¢ 8.2¢ 8.0¢ $63.52K 777.8K

Buyers (Bids)

No. Vol. Price($)
2 43377 8.0¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 97561 1
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.